Aging (Albany NY)
- JIANG Y, Yu Z, Zheng H, Zhou X, et al
An immune biomarker associated with EMT serves as a predictor for prognosis and
drug response in bladder cancer.
Aging (Albany NY). 2024;16.
Ann Surg Oncol
- ZHANG M, Wu J, Zhang Y, Shang H, et al
Recent Advances of Neoadjuvant Immunotherapy for Urothelial Bladder Cancer.
Ann Surg Oncol. 2024 Jul 12. doi: 10.1245/s10434-024-15725.
- WONG CH, Ko IC, Kang SH, Kitamura K, et al
ASO Visual Abstract: Long-Term Outcomes of Orthotopic Neobladder versus Ileal
Conduit Urinary Diversion in Robot-Assisted Radical Cystectomy (RARC):
Multicenter Results from the Asian RARC Consortium.
Ann Surg Oncol. 2024;31:5119-5120.
Arch Esp Urol
- CHENG H, Wang R, Lu L, Gong Y, et al
Bladder Cancer Patients with Elevated SPRR1B Expression Experiencing a Poor
Prognosis.
Arch Esp Urol. 2024;77:554-569.
- YORULMAZ EM, Kose O, Ozcan S, Gorgel SN, et al
Factors Influencing Bladder Perforation during Transurethral Resection of Bladder
Cancer: A Comprehensive Analysis.
Arch Esp Urol. 2024;77:471-478.
- PEREZ GONZALEZ S, Heredia-Soto V, Giron de Francisco M, Perez-Fernandez E, et al
Clinical, Pathological Characteristics and Progression of Urothelial Bladder
Cancer in Young Adult Patients. Our Experience and Literature Review.
Arch Esp Urol. 2024;77:463-470.
Asian J Surg
- CHEN TF, Chen HY, Jiang WL, Li SN, et al
A rare case of rapid progression from cystitis to bladder cancer.
Asian J Surg. 2024 Jul 9:S1015-9584(24)01403.
Biomater Sci
- ZHUANG S, Jin X, Cen L, Shao Y, et al
Encapsulation of hydroxycamptothecin within porous and hollow
poly(L-lactide-co-epsilon-caprolactone) microspheres as a floating delivery system for
intravesical instillation.
Biomater Sci. 2024;12:3659-3671.
Bladder Cancer
- RADVANYI F, Real FX, McConkey D
What is a Bladder Cancer Molecular Subtype? - Counterpoint.
Bladder Cancer. 2023;9:299-304.
- ABDELTWAB RM, Yacoub E, Rashad AH, Shohdy KS, et al
Molecular Basis of Tumorigenesis of Bladder Cancer and Emerging Concepts in
Developing Therapeutic Targets.
Bladder Cancer. 2023;9:313-322.
- MESSING EM
A New Standard of Care for Bladder Cancer.
Bladder Cancer. 2023;9:383-385.
- VAN ZUTPHEN M, Kiemeney LALM, Oldenhof UTH, Maurits JSF, et al
No Association Between BCG Instillations and COVID-19 Incidence in a Dutch
Non-Muscle Invasive Bladder Cancer Cohort.
Bladder Cancer. 2023;9:355-363.
- HOGLUND M
What is a Bladder Cancer Molecular Subtype?
Bladder Cancer. 2023;9:293-298.
- GRAJALES V, Contieri R, Tan WS, Flores M, et al
Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk
Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile.
Bladder Cancer. 2023;9:327-334.
- ASIMAKOPOULOS AD, Kochergin M, Colalillo G, Fahmy O, et al
New Intravesical Agents for BCG-Unresponsive High-Risk Non-Muscle Invasive
Bladder Cancer.
Bladder Cancer. 2023;9:237-251.
- AZURI W, Jaunarena JH, Camean JJ, Chemi J, et al
The Impact of Dose Reduction of Bacillus Calmette-Guerin on Oncological Outcomes
and Toxicity in Non-Muscle Invasive Bladder Cancer: A Systematic Review and
Meta-Analysis.
Bladder Cancer. 2023;9:227-236.
- MESSING EM
Y Chromosome Loss and Bladder Cancer.
Bladder Cancer. 2023;9:287-288.
- CHANG E, Hahn NM, Lerner SP, Fallah J, et al
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer.
Bladder Cancer. 2023;9:271-286.
- MENG XY, Wang QL, Shi MJ, Zhang HY, et al
Historical Pathogen-Driven Selection May Contribute to Contemporary Ethnic
Difference in Bladder Cancer Susceptibility.
Bladder Cancer. 2023;9:211-216.
- WANG YA, Ranti D, Bieber C, Galsky M, et al
NK Cell-Targeted Immunotherapies in Bladder Cancer: Beyond Checkpoint Inhibitors.
Bladder Cancer. 2023;9:125-139.
- ZHANG JH, Starr SL, Chamie K
Novel Delivery Mechanisms for Existing Systemic Agents and Emerging Therapies in
Bladder Cancer.
Bladder Cancer. 2023;9:109-123.
- MESSING EM
Neoadjuvant Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer.
Bladder Cancer. 2023;9:191-192.
- MELGAREJO SEGURA MT, Morales Martinez A, Yanez Castillo Y, Arrabal Polo MA, et al
Electromotive Drug Administration Chemotherapy with Mitomycin C Versus Bacillus
Calmette-Guerin for the Treatment of Non-Muscle Invasive Bladder Cancer.
Bladder Cancer. 2023;9:159-166.
- MOORE A, Lobaugh SM, Zhang Z, Rosenberg JE, et al
Hypofractionated Radiation Therapy (Hypo-RT) for the Treatment of Localized
Bladder Cancer.
Bladder Cancer. 2023;9:141-150.
- PARE JF, Tabasinezhad M, Grossman A, Atallah A, et al
Association of Histone H3 Trimethylation in Circulating Monocytes with Lack of
Early Recurrence in Patients with Bladder Cancer following BCG Induction Therapy.
Bladder Cancer. 2023;9:175-186.
- ALAM SM, Martin A, McLeay MT 2nd, Smith H, et al
Predictive Value of Computed Tomography Following Neoadjuvant Chemotherapy for
Muscle Invasive Bladder Cancer.
Bladder Cancer. 2023;9:167-174.
- SCHMITZ-DRAGER C, Goebell PJ, Paxinos E, Bismarck E, et al
Potential of an mRNA-Based Urine Assay (Xpert((R)) Bladder Cancer Detection(1)) in
Hematuria Patients - Results from a Cohort Study.
Bladder Cancer. 2024;10:25-33.
- DURANT AM, Lee YS, Mi L, Faraj K, et al
Effect of Bacille Calmette-Guerin for Non-Muscle-Invasive Bladder Cancer After
Prostate Radiotherapy.
Bladder Cancer. 2024;10:35-45.
- HEARD JR, Mitra AP
Noninvasive Tests for Bladder Cancer Detection and Surveillance: A Systematic
Review of Commercially Available Assays.
Bladder Cancer. 2024;10:71-81.
- SOLOWAY MS, Abrahams NA
Challenging Cases in Urothelial Cancer: Case 31: LG Ta Bladder Cancer.
Bladder Cancer. 2024;10:93-103.
- MCCONKEY DJ, Baumann BC, Cooper Greenberg S, DeGraff DJ, et al
Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for
Non-muscle Invasive Bladder Cancer.
Bladder Cancer. 2024;10:1-8.
Cell Mol Life Sci
- HUANG G, Liu J, Yu A, Luo C, et al
Nuclear translocation of ISG15 regulated by PPP2R2B inhibits cisplatin resistance
of bladder cancer.
Cell Mol Life Sci. 2024;81:292.
Clin Chim Acta
- GAO Y, Zhang X, Wang X, Sun R, et al
The clinical value of rapidly detecting urinary exosomal lncRNA RMRP in bladder
cancer with an RT-RAA-CRISPR/Cas12a method.
Clin Chim Acta. 2024 Jul 7:119855. doi: 10.1016/j.cca.2024.119855.
Crit Rev Anal Chem
- CHENG K, Wan S, Yang JW, Chen SY, et al
Applications of Biosensors in Bladder Cancer.
Crit Rev Anal Chem. 2024 Jul 8:1-20. doi: 10.1080/10408347.2024.2373923.
Curr Med Chem
- ABAZARI O, Dayati P, Shahidi M, ZavarReza J, et al
Exploring a Desirable Quadr-mRNAs Panel for Non-invasive and Ultrasensitive
Bladder Cancer Diagnosis: In-silico and Clinical Studies.
Curr Med Chem. 2024 Jul 8. doi: 10.2174/0109298673302140240627053904.
Curr Med Sci
- WANG L, Wang P, Liu B, Zhang H, et al
LncRNA MEG3 Inhibits the Epithelial-mesenchymal Transition of Bladder Cancer
Cells through the Snail/E-cadherin Axis.
Curr Med Sci. 2024 Jul 11. doi: 10.1007/s11596-024-2895.
Cytometry A
- WEI S, Lei C
Noninvasive detection for bladder cancer: Quantitative interferometric imaging
flow cytometry.
Cytometry A. 2024 Jul 10. doi: 10.1002/cyto.a.24887.
Environ Geochem Health
- CHUNG YL, Lin MH, Liaw YP, Guo HR, et al
Dose-response relationship between arsenic in drinking water and mortality of
urinary cancers in Taiwan.
Environ Geochem Health. 2024;46:299.
Fr J Urol
- SAINT F, Pasquier D, Villers A, Massa J, et al
Incidence, initial management and survival of high-risk non-muscle invasive
bladder cancer in Northern France.
Fr J Urol. 2024 Jul 3:102675. doi: 10.1016/j.fjurol.2024.102675.
Front Immunol
- ZHANG X, Pei Z, Ren J, Shi J, et al
PA-MSHA improves prognosis of patients undergoing radical cystectomy: a
retrospective cohort study using inverse probability of treatment weighting.
Front Immunol. 2024;15:1403302.
Front Pharmacol
- XU Z, Zhao Y, Zhang Y, Liu X, et al
Prediction of immunotherapy response of bladder cancer with a pyroptosis-related
signature indicating tumor immune microenvironment.
Front Pharmacol. 2024;15:1387647.
Heliyon
- LIU J, Zhijin Z, Zhang W, Niraj M, et al
Urinary exosomes: Potential diagnostic markers and application in bladder cancer.
Heliyon. 2024;10:e32621.
Hereditas
- HAN D, Xiong B, Zhang X, Chen C, et al
Knockdown of AMIGO2 suppresses proliferation and migration through regulating
PPAR-gamma in bladder cancer.
Hereditas. 2024;161:21.
Int Immunopharmacol
- WANG Z, Chen DN, Huang XY, Zhu JM, et al
Machine learning-based autophagy-related prognostic signature for personalized
risk stratification and therapeutic approaches in bladder cancer.
Int Immunopharmacol. 2024;138:112623.
Int J Biol Sci
- HUANG C, Yang Y, Wang X, Chen S, et al
PTBP1-mediated biogenesis of circATIC promotes progression and cisplatin
resistance of bladder cancer.
Int J Biol Sci. 2024;20:3570-3589.
J Cancer Res Clin Oncol
- STORMOEN DR, Rohrberg KS, Mouw KW, Orum K, et al
Similar genetic profile in early and late stage urothelial tract cancer.
J Cancer Res Clin Oncol. 2024;150:339.
J Magn Reson Imaging
- YU R, Cai L, Cao Q, Liu P, et al
Development and Validation of an MRI-Based Nomogram for Preoperative Detection of
Muscle Invasion in VI-RADS 3.
J Magn Reson Imaging. 2023 Oct 30. doi: 10.1002/jmri.29103.
J Med Case Rep
- ISHIDA N, Nagata K, Fukuda J, Oguma Y, et al
Stereotactic body radiation therapy for multiple lung cancers in a patient with
six primary cancers: a case report.
J Med Case Rep. 2024;18:316.
J Nippon Med Sch
- HONDA Y, Sekine T, Kimata R, Motoda N, et al
Early and Post-Treatment Imaging Findings in Perineural Spread: A Pathway to
Diffuse Muscle Metastasis in Recurrent Bladder Carcinoma.
J Nippon Med Sch. 2024;91:333-338.
J Occup Environ Med
- GARIAZZO C, Massari S, Consonni D, Marchetti MR, et al
Cancer-Specific Mortality Odds Ratios in the Food, Accommodation, and Beverage
Activities in Italy.
J Occup Environ Med. 2024;66:572-579.
J Pathol
- SZARVAS T, Reis H
Beyond driver mutations: exploring the landscape of mutational signatures in
adenocarcinomas of the bladder(dagger).
J Pathol. 2024;263.
J Transl Med
- WU C, Wei X, Huang Z, Zheng Z, et al
Urinary microbiome dysbiosis is associated with an inflammatory environment and
perturbed fatty acids metabolism in the pathogenesis of bladder cancer.
J Transl Med. 2024;22:628.
J Urol
- CHANG SS
Urologic Oncology: Bladder, Penis, and Urethral Cancer, and Basic Principles of
Oncology.
J Urol. 2024 May 17:101097JU0000000000004018. doi: 10.1097/JU.0000000000004018.
J Zhejiang Univ Sci B
- ZENG S, Xing S, Zhang Y, Wang H, et al
Nano-Bacillus Calmette-Guerin immunotherapies for improved bladder cancer
treatment.
J Zhejiang Univ Sci B. 2024 Jul 9:1-11. doi: 10.1631/jzus.B2300392.
Jpn J Clin Oncol
- YOKOYAMA M, Chen W, Waseda Y, Fujiwara M, et al
Comparisons of in-hospital fee and surgical outcomes between robot-assisted,
laparoscopic, and open radical cystectomy: a Japanese nationwide study.
Jpn J Clin Oncol. 2024;54:822-826.
Med Oncol
- CHOU WH, Wang A, Bassale S, Latour E, et al
Utilization of neoadjuvant chemotherapy for muscle-invasive bladder cancer in
elderly patients: a retrospective cohort study.
Med Oncol. 2024;41:197.
Med Phys
- XIONG S, Fu Z, Deng Z, Li S, et al
Machine learning-based CT radiomics enhances bladder cancer staging predictions:
A comparative study of clinical, radiomics, and combined models.
Med Phys. 2024 Jul 8. doi: 10.1002/mp.17288.
Nutr Cancer
- ABOU CHAKRA M, Duquesne I, Peyromaure M, Mott SL, et al
A Multinational, Multi-Institutional Study Assessing the Impact of Diabetes
Mellitus on the Prognosis of Patients with Non-Muscle Invasive Bladder Cancer
Treated with Bacillus Calmette-Guerin.
Nutr Cancer. 2024 Jul 7:1-9. doi: 10.1080/01635581.2024.2374046.
Target Oncol
- GUPTA S, Moon HH, Sridhar SS
A Podcast on Platinum Eligibility and Treatment Sequencing in Platinum-Eligible
Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
Target Oncol. 2024;19:483-494.
- UCHIMOTO T, Matsuda T, Komura K, Fukuokaya W, et al
C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab
Vedotin in Metastatic Urothelial Carcinoma.
Target Oncol. 2024;19:635-644.
Transl Androl Urol
- AKINSOLA OA, Talwar R, Baskin A, Luckenbaugh AN, et al
Use of atezolizumab in bacillus Calmette-Guerin-unresponsive high-risk
non-muscle-invasive bladder cancer.
Transl Androl Urol. 2024;13:1061-1063.
- LINDSKROG SV, Dyrskjot L
Towards circulating tumor DNA-guided treatment of muscle-invasive bladder cancer.
Transl Androl Urol. 2024;13:1056-1060.
Transl Cancer Res
- CHEN K, Chen S, Wu S, Sun G, et al
Prognostic value of GARS in bladder cancer and its role in the tumor
microenvironment.
Transl Cancer Res. 2024;13:2825-2846.
World J Methodol
- XIANG L, Xie QQ, Xu SS, Ruan WJ, et al
Association between tobacco exposure and bladder cancer recurrence: A systematic
review and meta-analysis.
World J Methodol. 2024;14:91889.
World J Psychiatry
- LU B, Ding M, Xu HB, Yan CY, et al
Status quo and factors of depression and anxiety in patients with non-muscle
invasive bladder cancer after plasma electrocision.
World J Psychiatry. 2024;14:822-828.
World J Urol
- SONG Y, Xu T
Gender difference of bladder cancer: insights from hormone, anatomy and tumor
microenvironment.
World J Urol. 2024;42:401.
- SANO T, Yoshida T, Nakamoto T, Ohe C, et al
Diagnostic performance of photodynamic diagnosis with oral 5-aminolevulinic acid
for upper tract- and bladder urothelial carcinoma: a single-centre, retrospective
analysis.
World J Urol. 2024;42:389.
Zhonghua Yi Xue Za Zhi
- WANG MS, Zhang SH, Wang JW, Jia BL, et al
[Functional analysis of laparoscopic intracorporeal Xing's neobladder in
long-term follow-up].
Zhonghua Yi Xue Za Zhi. 2024;104:2449-2451.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016